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Background: Glioblastoma (GBM), being a highly vascularised and locally invasive tumour, is an attractive target for anti-
angiogenic and anti-invasive therapies. The GBM/endothelial cell response to gossypol/temozolomide (TMZ) treatment was
investigated with a particular aim to assess treatment effects on cancer hallmarks.
Methods: Cell viability, endothelial tube formation and GBM tumour cell invasion were variously assessed following combined
treatment in vitro. The U87MG-luc2 subcutaneous xenograft model was used to investigate therapeutic response in vivo. Viable
tumour response to treatment was interrogated using immunohistochemistry. Combined treatment protocols were also tested in
primary GBM patient-derived cultures.
Results: An endothelial/GBM cell viability inhibitory effect, as well as an anti-angiogenic and anti-invasive response, to combined
treatment have been demonstrated in vitro. A significantly greater anti-proliferative (P¼ 0.020, P¼ 0.030), anti-angiogenic
(P¼ 0.040, Po0.0001) and pro-apoptotic (P¼ 0.0083, P¼ 0.0149) response was observed when combined treatment was compared
with single gossypol/TMZ treatment response, respectively. GBM cell line and patient-specific response to gossypol/TMZ
treatment was observed.
Conclusions: Our results indicate that response to a combined gossypol/TMZ treatment is related to inhibition of tumour-
associated angiogenesis, invasion and proliferation and warrants further investigation as a novel targeted GBM treatment strategy.
Glioblastoma (GBM) represents the most common and aggressive
form of malignant brain tumour and is classified as a grade IV
glioma by the World Health Organization. It is characterised by the
presence of multifocal necrosis, microvascular proliferation, local
tumour cell invasion and inherent resistance to apoptosis (Louis
et al, 2007). Despite current standard of care, which includes
surgery, radiation and chemotherapy with the alkylating agent
temozolomide (TMZ), survival rates for GBM remains low.
Median survival for patients is just 14 months from the time of
diagnosis (Stupp et al, 2005, 2009).
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Angiogenesis has a crucial role in GBM tumour growth,
maintenance and local spread throughout the brain. The formation
of abnormal vasculature and local tumour cell invasion often
results in resistance to conventional treatment (Onishi et al, 2011).
Therefore, as we have previously suggested (Jarzabek et al, 2013b),
the development of novel therapeutics, which inhibit more than
one ‘hallmark of cancer’ (e.g., angiogenesis, GBM cell invasion,
proliferation and/or apoptosis) and which act synergistically with
standard treatment regimens, remains a critical objective.
One promising approach may be inhibition of pro-survival
B-cell lymphoma (Bcl-2) proteins (Azmi and Mohammad, 2009).
It has been demonstrated that Bcl-2 proteins enhance tumour
progression (through inhibition of apoptosis) (Adams and Cory,
2007; Chipuk et al, 2010), neo-angiogenesis (through induction of
the hypoxia-inducible factor-1 transcription factor, endothelial cell
survival and VEGF) (Biroccio et al, 2000; Fernandez et al, 2001;
Kumar et al, 2008), tumour invasion (through induction of matrix
metalloproteinases (MMPs)) (Wick et al, 1998; Choi et al, 2005)
and resistance to chemotherapeutic agents, such as TMZ (Krakstad
and Chekenya, 2010). Moreover, upregulated Bcl-2 expression
has been shown in microvascular endothelial cells resulting
in increased tumour angiogenesis and tumour growth (Nor et al,
2001).
Gossypol, a small molecule, naturally occurring BH3 mimetic, is
a cottonseed-derived polyphenolic compound that has been
extensively tested in humans as a male contraceptive agent (Qian
and Wang, 1984), where it was shown to preferentially inhibit
cellular energy metabolism by inhibiting redox reactions catalysed
by lactate dehydrogenase A (LDH-A) (Javed and Khan, 1999;
Conners et al, 2005). Gossypol binds to the BH3 groove of Bcl-2
(Ki¼ 320 nM), Bcl-XL (Ki¼ 480 nM) and Mcl-1 (Ki¼ 180 nM)
(Qiu et al, 2002) and decreases the proliferation of many human
cancer cells both in in vitro and in vivo settings (Mohammad et al,
2005; Wolter et al, 2006; Meng et al, 2008; Pang et al, 2011),
including GBM (Coyle et al, 1994; Voss et al, 2010). Recent studies
suggest a direct role for the drug in suppression of angiogenesis
(Pang et al, 2011) and metastatic behaviour (Huang et al, 2009;
Jiang et al, 2011).
Gossypol has also been tested in patients with recurrent or
progressive GBM in early clinical trials. It has been shown to be
well tolerated at a dose of 20mg day 1 and has a low, but
measurable, response rate (Bushunow et al, 1999). In addition, two
clinical trials with gossypol have been completed: (i) a phase II trial
to determine the acute and late toxicity of single-agent gossypol
treatment with patients having progressive or recurrent GBM
(NCT00540722) and (ii) a non-randomised phase I trial to
investigate the side effects and dosage of gossypol in combination
with TMZ with or without radiation therapy with patients having
newly diagnosed GBM (NCT00390403). Results from these clinical
studies are not yet available.
In the present study, the response to targeting multiple
‘hallmarks of cancer’ with gossypol, alone and in combination
with TMZ, in GBM was investigated, implementing in vitro and
in vivo disease models. Synergy and/or additive effects of the
combined treatment were assessed in vitro, as well as the pro-
apoptotic, anti-proliferative, anti-angiogenic and anti-tumour
invasive response.
MATERIALS AND METHODS
Reagents. Gossypol and TMZ were purchased from Sigma-
Aldrich, St. Louis, MO, USA. For in vitro experiments, reagents
were dissolved in DMSO at 100mM stock solution. For in vivo
studies, gossypol was solubilised in a vehicle solution of 10%
ethanol in sterile dH2O (Xu et al, 2005), whereas TMZ was
formulated in a vehicle solution of 10% DMSO in sterile D-PBS
(Pedretti et al, 2010) as previously described. Both agents were
freshly prepared before each administration.
Cell cultures. U87MG-luc2 GBM cell line was purchased from
Caliper Life Science (A PerkinElmer Company, Hopkinton, MA,
USA) and cultured in Eagle’s Minimum Essential Medium
(EMEM) (Gibco, Invitrogen, Carlsbad, CA, USA). U251, U373
and U343 GBM cell lines were purchased from the American
Tissue Culture Collection (ATCC, Rockville, MD, USA) and
cultured in high-glucose (4500mg l 1) Dulbecco’s Modified
Eagle’s Medium (DMEM) (Lonza, Basel, Switzerland). EMEM
and DMEM were supplemented with 10% heat-inactivated foetal
bovine serum (FBS), 1% L-glutamine (2mM) and 1% penicillin/
streptomycin (50 unitsml 1), all from Sigma-Aldrich. Human
umbilical vein endothelial cells (HUVECs) were purchased
from Lonza and maintained in Endothelial Cell Basal Medium-2
(EBM-2, Lonza). Each 500ml of EBM-2 was supplemented with
EGM-2 SingleQuots Kit (Lonza) consisting the following growth
supplements: human epidermal growth factor (hEGF), 0.5ml;
vascular endothelial growth factor (VEGF), 0.5ml; R3-insulin-like
growth factor-1 (R3-IGF-1), 0.5ml; ascorbic acid, 0.5ml; hydro-
cortisone, 0.2ml; human fibroblast growth factor-beta (hFGF-b),
2.0ml; heparin (0.5ml); fetal bovine serum (FBS), 25.0ml;
gentamicin/amphotericin-B (GA), 0.5ml. All cells were maintained
at 37 1C in humidified air with 5% CO2.
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide,
a yellow tetrazole (MTT)-based cell viability assay. Cell viability
was determined using the MTT reagent (Sigma-Aldrich). GBM cell
lines or HUVECs were seeded into 96-well cell culture plates (2000
GBM cells 100 ml 1 well 1 or 5000 HUVECs 100 ml 1 well 1).
Following incubation (24 h), 100 ml of medium with or without test
agent(s) was added into appropriate wells and incubated for the
desired periods. Following incubation, 20 ml of MTT in D-PBS
(5mgml 1) was added to each well. After 4 h, medium was
replaced with 100 ml of DMSO in order to dissolve MTT formazan
product. Absorbance was read on a spectrophotometer at 560 nm.
Drug concentrations causing 50% cell growth inhibition (IC50
values) were calculated for single drug treatment via a sigmoidal
dose–response curve using GraphPad Prism version 5.00 for
Windows (Graphpad, San Diego, CA, USA). The dose–effect
analysis by Chou and Talalay (1984) was used to assess the
interaction between gossypol and TMZ. Determination of the
synergistic, additive and/or antagonistic cytotoxic effects of
the combined treatment of GBM cells and HUVECs was assessed
using the CompuSyn for Drug Combinatios and for General Dose-
Effecr Analysis software (ComboSyn, Inc., Paramus, NJ, USA). The
combination index (CI) was used to express synergism (CIo1),
additive effect (CI¼ 1) or antagonism (CI41).
In vitro endothelial cell capillary-like tube formation assay.
HUVECs were seeded into 96-well cell culture plate coated with
matrigel (BD Biosciences, Franklin Lakes, NJ, USA) in the absence/
presence of agent(s). Cells were incubated for up to 20 h at 37 1C in
CO2 incubator. Tube formation was observed under a phase-
contrast microscope (Nikon, Tokyo, Japan) and a charge-coupled
device camera (SPOT RT SE 6; Diagnostic Instruments, Inc.,
Sterling Heights, MI, USA) at  200 magnification. Four randomly
chosen microscopic fields per well were photographed with a
digital camera. The number of branch-points per field-of-view was
counted, and the length of tubules was quantified using the ImageJ
1.44 software (NIH, Bethesda, MD, USA).
3-D invasion assay. GBM cell line spheroids were formed using
the hanging drop method previously described (Del Duca et al,
2004). Following incubation (48 h), cell aggregates were transferred
to a 100-mm dish coated with 2% agar filled with 10ml of growth
medium. Following incubation (48 h), spheroids were implanted
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into collagen gel (one spheroid per well and 500 ml of collagen
solution per well in 24-well plate). Chilled PureCol Bovine Collagen
Product 3mgml 1 (Nutacon BV, Leimuiden, The Netherlands)
was mixed with 10-fold concentrated Dulbecco’s minimal essential
medium (Sigma-Aldrich) and cold 0.1M sodium hydroxide
(Sigma-Aldrich) at a ratio of 8 : 1 : 1. pH was neutralised by adding
1M NaOH (Sigma-Aldrich). Following incubation in 37 1C (1 h),
500 ml of complete growth medium was added to each well and
returned to incubator. Gossypol (either with or without TMZ) was
re-suspended in growth medium and added to the collagen gel
matrix 2 days after implantation of spheroids into collagen gel
(when invasion had already started). Cell invasion out of the
spheroid was measured before treatment commenced (day 0) and
on days: 2, 6, 8, 13 and 15, using a grated objective, a phase-
contrast microscope (Nikon). Images were taken with a charge-
coupled device camera (SPOT RT SE 6; Diagnostic Instruments,
Inc.) at day 15. Alternatively, a 3-D matrigel invasion assay was
performed as previously described (Kwiatkowska et al, 2012) with
minor modifications. Briefly, 1 105 of U87MG-luc2 cells were re-
suspended in 50 ml of BD Matrigel and added to the top well (BD
Falcon Cell culture inserts for 24-well plates, 8.0-mm pores,
Translucent PET Membrane (BD Biosciences, Franklin Lakes, NJ,
USA)). Following incubation at 37 1C for 30min, 200 ml of serum-
free growth medium with or without drug(s) was added to the top
well and 700 ml of serum containing growth medium with or
without drug(s) to the bottom well. After 48 h, cells attached to the
bottom of insert were fixed and stained with 0.5% methylene blue
dissolved in dH2O (Sigma-Aldrich). Cells on the upper surface of
the filter were wiped off with a Q-tip. Images were taken using a
colour device camera.
GBM xenograft model and drug treatment. All animal experi-
ments were licensed by the Department of Health and Children in
Ireland. Study protocols were reviewed by the Animal Research
Ethics Committee (AREC) at the University College Dublin.
Female BALB C nu/nu mice (4–6 weeks) were procured at the SPF-
grade Conway Institute Biotechnical Services (CIBS) Xenograft
Facility from Harlan Laboratories, UK, Ltd., Bicester, UK. Mice
were anesthetised with O2/isoflurane mixture, and 5 106 of
U87MG-luc2 cells suspended in 100 ml of matrigel/D-PBS mixture
(50 : 50) were inoculated subcutaneously in the right flank of the
animal. Tumour dimensions were measured by calliper, and
volumes estimated by the formula: a2 b 0.5, where a and b are
the shorter and longer diameter of the tumours, respectively. When
tumours reached approximately 200mm3 (approximately 28 days
following inoculation), mice were randomised into treatment
groups. No difference in mean tumour volume was observed
among the treatment groups at day 0 before treatment commence-
ment. Group 1 (n¼ 8) received 30mg kg 1 of gossypol by oral
gavage (p.o.), using a regiment of daily dosing for 5 consecutive
days, followed by a 2-day rest, before resuming dosing. Group 2
(n¼ 6) was treated with 7.5mg kg 1 of TMZ by intraperitoneal
injection (i.p.) daily for 9 consecutive days. Group 3 (n¼ 8)
received both gossypol and TMZ treatments using the same
regimens as above. On days when both drugs were administered,
TMZ was administered at least 5 h after gossypol. The control
cohort received an equivalent volume of vehicle for gossypol (10%
ethanol in sterile dH2O) and TMZ (10% DMSO in sterile D-PBS).
All animals were monitored for adverse effects. When tumours
exceeded 15mm in any of the diameters, animals were euthanised.
Histological examination and immunohistochemistry. Subcuta-
neous tumours were excised, rinsed twice in D-PBS and fixed in
4% formaldehyde for 48 h. Tissues were embedded in paraffin and
5-mm thick sections were cut. Sections were deparaffinised with
histoclear II and re-hydrated according to standard histological
procedures. Routine hematoxylin and eosin (H&E) staining was
performed to facilitate histological evaluation by a veterinary
pathologist. For immunohistochemistry, epitope retrieval was
performed by microwave boiling for 20min in 10mM citrate
buffer at pH 6.0. One hour blocking in 5% serum/TBS-T was used
before primary antibody incubation (rabbit anti-human Ki67
(Millipore, Billerica, MA, USA, dilution 1 : 100) for 1 h in room
temperature or goat anti-PECAM-1/Cd31 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA, dilution 1 : 100) overnight at 4 1C).
Biotinylated goat anti-rabbit or horse anti-goat secondary anti-
body, respectively (Vector Laboratories, Burlingame, CA, USA,
dilution 1 : 200), were applied for 1 h at room temperature followed
by ABC-complex (Vectastain ABC kit, Vector Laboratories)
incubation for 30min. Signal was developed with diaminobenzi-
dine (DAKO Cytomation, Glostrup, Denmark) according to the
manufacturer’s instructions. Sections were counterstained with
hematoxylin (Sigma-Aldrich) to visualise nuclei. For assessment of
proliferation indices, percentage of Ki-67-positive cells in the viable
areas of tumours was quantified under a light microscope, using an
objective with grid-graticula. Microvessel density was assessed
using an anti-PECAM-1/CD31 antibody. Vessel counts were
performed as previously described (Leonard et al, 2008).
TUNEL staining. The ApopTag Peroxidase In Situ Apoptosis
Detection Kit (Millipore) was used to detect apoptotic cells in situ
according to the manufacturer’s protocol.
Human GBM tumour-derived multicellular spheroid culture.
Human GBM tumour-derived spheroids (patient 3) were kindly
provided by Professor Rolf Bjerkvig (University of Bergen) and
expanded in vivo via serial transplantation into immunocompro-
mised rodents as previously described (Bjerkvig et al, 1990; Wang
et al, 2009; Johannessen et al, 2009). Human GBM tumour-derived
multicellular spheroids were maintained for short term in vitro in
complete growth medium (DMEM (Sigma-Aldrich), containing
10% FBS supplemented with nonessential amino acids, 100Uml 1
penicillin/streptomycin and 400mM L-glutamine (all from
Cambrex, East Rutherford, NJ, USA) as previously described
(Jarzabek et al, 2013a).
Human GBM tumour-derived neurosphere lines culture. GBM
neurosphere lines (BT224-luc2 and BT248-luc2) were derived from
Brigham and Women’s Hospital patients undergoing surgery
according to IRB-approved protocols as previously described
(Mehta et al, 2011; Koivunen et al, 2012). Briefly, GBM tumour
resection samples were mechanically dissociated, and neurospheres
were established and propagated in in Complete Human
NeuroCult NS-A Proliferation Medium that contains NeuroCult
NS-A Basal Medium, NeuroCult NS-A Proliferation Supplements,
20 ngml 1 rh-EGF, 10 ngml 1 rh-bFGF and 2mgml 1 heparin
(StemCell Technologies, Vancouver, BC, Canada) as previously
described (Inda et al, 2010). Cells were maintained and expanded
in ultra-low-attachment 25-cm2 cell culture vessels. Luciferase
expression of human GBM tumour-derived neurosphere lines was
performed as previously described using pMMP-LucNeo retrovirus
(Rubin et al, 2003). Human GBM tumour-derived BT-224-luc2
and BT248-luc2 neurosphere lines used in this study were passaged
not more than 10 times.
Human GBM tumour-derived spheroids and neurosphere lines
in vitro viability assays. Human GBM tumour-derived spheroids
were transferred to 96-well plate (one spheroid per well) and
cultured in complete growth medium as previously described
(Johannessen et al, 2009). Whereas, GBM patient-derived neuro-
spheres were mechanically dissociated and re-suspended in
complete NeuroCult medium and seeded 2000 cells per 100 ml of
complete NeuroCult medium per well as previously described
(Ziegler et al, 2011). Following overnight culture, 100 ml of
complete growth medium containing DMSO (control wells) or
drug(s) in appropriate concentration (treated wells) were added.
Following incubation (37 1C in humidified air with 5% CO2 for
Gossypol/temozolamide combined therapy in glioblastoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.529 2277
96 h), 20 ml of MTT/PBS (5mgml 1) was added into each well.
Following incubation (4 h), plates were spun down at 2000 r.p.m.
for 5min. Subsequently, media containing MTT solution was
carefully removed from each well, and crystals were dissolved in
100 ml of DMSO. Well content was agitated for 15min on a micro-
plate shaker. Finally, absorbance at 560 nm of the resulting solution
was measured using a micro-plate reader (Tecan Group Ltd,
Ma¨nnedorf, Switzerland).
Statistical methods. For statistical comparison, a mixed-model
linear test analysis (SPSS, IBM Corporation, Armonk, NY, USA),
unpaired t-test or one-way analysis of variance (ANOVA) followed
by Tukey’s post-hoc test (GraphPad Prism version 5.00 for
Windows, San Diego, CA, USA) was employed.
RESULTS
Gossypol acts synergistically with TMZ to inhibit endothelial
cells (HUVECs) and GBM (U87-MG-luc2 and U343) cell
lines. To investigate the dose-dependent cytotoxic effect of
gossypol on GBM and endothelial cells and to estimate and
compare IC50 concentrations, four GBM cell lines (U87MG-luc2,
U251, U373, U343) (Figure 1A) and HUVECs (Figure 1B) were
treated with different concentrations of gossypol for 72 h. Mean
IC50 values, for each GBM cell line and endothelial cells, were
obtained. Enhanced gossypol cytotoxicity was observed in
HUVECs showing lowest IC50 concentration (1.699±0.178) when
compared with IC50 concentrations derived for four different GBM
cell lines. Among the GBM cell lines tested, U251 and U373
exhibited higher IC50 values following 72 h treatment
(11.600±4.353 and 10.120±2.931, respectively) when compared
with U343 and U87 cell lines (5.784±0.458 and 5.689±0.487,
respectively) (Figure 1C).
To examine the sensitivity of GBM cells to combined gossypol/
TMZ treatment, U87MG-luc2, U251, U373 and U343 cells were
exposed to various concentrations of gossypol (3, 6 or 12 mM) either
with or without differing concentrations of TMZ (100, 200 or
400 mM) for 96 h (Figure 2). Maximum growth inhibition (400 mM
TMZ) did not exceed 52, 53, 27 or 52% in U87MG-luc2, U251,
U343 or U373 cell lines, respectively. Addition of gossypol
enhanced the anti-proliferative effect of TMZ, increasing growth
inhibition to 89, 70, 63 or 82%,, respectively, in U87MG-luc2,
U251, U343 or U373 cell lines (one-way ANOVA, Po0.05).
Combining TMZ with gossypol (3 mM) potentiated the effect of
gossypol alone (Figure 2A, C, E and G). Isobologram analysis was
employed to further investigate whether observed gossypol and
TMZ interactions were antagonistic, additive or synergistic.
CI values o, ¼ or 41 indicate synergy, additive effect or
antagonism, respectively. The greatest synergistic interaction was
observed in the U343 cell line, some synergistic interaction was
observed in U87MG-luc2 cell line, whereas U251 and U373 cell
lines exhibited additive and antagonistic responses to gossypol/
TMZ treatment (Figure 2B, D, F, H and K).
Next, sensitivity of HUVECs to combined gossypol/TMZ
treatment was examined. HUVECs were exposed to various
concentrations of gossypol (1.5, 3 or 6 mM) either with or without
various concentrations of TMZ (50, 100 or 200 mM) for 72 h. As
HUVECs are more sensitive to gossypol treatment, lower drug
concentrations and shorter incubation times were used to assess
treatment efficacy. Maximum growth inhibition with 200 mM of
TMZ did not exceed 30%. Nevertheless, the addition of gossypol
greatly enhanced the anti-proliferative effect of TMZ, causing up to
88% growth inhibition in HUVECs. Combining TMZ with 1.5 mM
gossypol appeared to potentiate the effect of single-agent gossypol
(Figure 2I). Similarly, in order to further analyse drug combination
response in HUVECs, isobologram analysis was performed.
Analysis of CIs provided evidence that the majority of treatment
conditions implemented in HUVEC studies promoted synergistic
cell killing (Figure 2J and K).
Gossypol in combination with TMZ treatment inhibits HUVEC
tube formation in vitro. In order to further examine the effects of
gossypol/TMZ treatment on the final step of angiogenesis,
(tubulogenesis), we employed an in vitro tubule-formation assay
(Figure 3A–H). Tubule length (Figure 3I) and branch point
(Figure 3J) analyses demonstrated significant inhibition of both
tubule length and branch points in a dose-dependent manner
following 20-h gossypol/TMZ treatment (Po0.05 when compared
with control). Moreover, comparison of combined gossypol/TMZ
treatment with single-agent TMZ treatment revealed a significant
decrease in the total tubule length (when gossypol was used at 3, 6
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Figure 1. Gossypol reduces endothelial and GBM cell viability in a
dose-dependent manner. (A) The human GBM cell lines (U251, U373,
U343, U87MG-luc2) and (B) HUVECs were exposed to various
concentrations of gossypol for 72 h. GBM/endothelial cell viability was
assessed using the MTT-based cell viability assay. Each treatment
condition was replicated in at least three wells and in three
independent experiments. (C) IC50 concentrations were estimated
based on sigmoidal dose–response curves using the GraphPad
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presented.
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or 12 mM concentrations) and number of branch points (when
gossypol was used at 6 or 12 mM concentrations). Comparison of
combined gossypol/TMZ treatment with single gossypol treatment
showed a significant decrease in the total tubule length and
number of branch points when gossypol was implemented at
concentrations of 3 and 6 mM (Figure 3I and J).
Gossypol in combination with TMZ treatment inhibits GBM cell
invasion in vitro. To investigate GBM cell invasion following
gossypol±TMZ treatment in vitro, we first employed a 3-D
spheroid invasion assay using the U87MG-luc2 GBM cell line. In a
control setting, U87MG-luc2 GBM cells demonstrated invasive
activity reaching a distance of 3746.528±127.625 mm from parent
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Figure 2. Synergistic response to gossypol and TMZ combination therapy in GBM cell lines and primary endothelial cultures. (A–H) GBM and
(I, J) endothelial cells were exposed to increasing concentrations of gossypol and/or TMZ for 96 or 72 h, respectively. Cell viability was assessed
using the MTT assay. Each treatment condition was replicated in at least three wells and in three independent experiments. Means±s.e.m.
of three independent experiments are presented. *Po0.05 compared with control (0 mM gossypolþ 0 mM TMZ), one-way ANOVA and Tukey’s
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Gossypol/temozolamide combined therapy in glioblastoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.529 2279
spheroid within 15 days. U87MG-luc2 cells treated with gossypol
(3, 6 or 12 mM)/TMZ (100 mM) combination invaded to a lesser
extent from the spheroid core through the collagen gel
(Figure 4A–H). Significant anti-invasive effects of U87MG-luc2
cells treated with the combination regimen were observed in
comparison to the invasion distance in control wells commencing
from day 6 when 3mM of gossypol was used and from day 4 when
higher concentration (6 or 12 mM) of gossypol was used in
combination with TMZ (100 mM) treatment. Moreover, spheroids
treated with combined gossypol/TMZ treatment showed a
significant difference when compared with single treatments as
indicated in Figure 4I–K. Quantification of average invasion
distance per day revealed that spheroids treated with the
combination regimen gossypol (6 or 12 mM)/TMZ (100 mM) invaded
at a significantly slower rate when compared with control
(Figure 4L). The in vitro effect of gossypol treatment delivered in
combination with TMZ on GBM cell invasion was further
confirmed in 3-D matrigel invasion assay using trans-well Boyden
chambers as shown in Supplementary Figure S1A–H.
Gossypol in combination with TMZ inhibits GBM cell
proliferation, tumour angiogenesis and enhances apoptosis in
an in vivo GBM setting. To investigate the in vivo effect of
gossypol either with or without TMZ on tumour growth,
proliferation, apoptosis and angiogenesis, we employed a sub-
cutaneous GBM (U87MG-luc2) xenograft mouse model. Tumour
growth was measured over time. Figure 5A presents study time
points for drug combination treatment, BLI and caliper measure-
ment. Figure 5B shows the mean tumour volume based on calliper
measurements over time, and Figure 5C shows bioluminescence
images of representative tumours at day 14. As revealed by calliper
measurements, tumour volume in the vehicle-treated group
indicates rapid and robust tumour growth. An inhibitory effect
on tumour growth was observed in animals treated with
gossypol±TMZ. However, calliper measurements revealed a
significant difference in tumour volume only when combined
therapy was compared with single-agent gossypol treatment
(P¼ 0.002) and not when compared with single-agent TMZ
treatment (P¼ 0.496) (Figure 5B). Nevertheless, extensive necrotic
tumour cores were visible in BLI. Lack of bioluminescence signal or
signal reduction in the tumour core indicates haemorrhagic and
necrotic areas in rapidly growing tumours (Figure 5C). Differences
in the incidence of extensively necrotic tumours between treatment
cohorts were observed. Eighty-seven percent of mice displayed an
aggressive necrotic phenotype in control cohort, whereas in the
single-agent treatment groups (gossypol and TMZ, respectively)
this number was reduced to 62% and 50% of mice that had
extensive necrotic core. The greatest reduction, only 37% of
animals that had necrotic core, was observed in the combination
gossypol/TMZ-treated group (Figure 5D).
Further histological analysis of tumour phenotype revealed that
control tumours comprised a non-encapsulated densely cellular
mass with numerous monomorphic, mononuclear tumour cells
similar to the gossypol-treated cohort. Cells were arranged in
sheets and clusters in a fine fibrovascular stroma. Necrosis (most
likely due to large tumour size/fast growing tumour) was often
accompanied by a prominent influx of neutrophils, particularly at
the junction of viable and necrotic tissue. In contrast, TMZ
monotherapy and combined treatment showed marked distortion
of tumour architecture and a prominence of mononuclear giant
tumour cells with pleomorphic nuclei and an abundant eosino-
philic cytoplasm. Moreover, the pattern of tight clustering of cells
in a fibrovascular stroma (seen in vehicle and gossypol cohorts)
was frequently lost in regions rich in mononuclear giant cells. Cells
in these regions were more loosely arranged and lacking cluster
architectures. We observed reduced necrosis in TMZ- and
combination-treated tumours. Moreover, control tumours revealed
numerous mitotic figure (45 mitotic figures per high power field
(hpf)), whereas tumours treated with either single or combined
therapies revealed decreased numbers of mitotic figures
(0–3 mitotic figures per hpf) (Figure 5E (H&E images)).
A mean count of Ki-67-positive nuclei of 24.86±1.42 was
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observed in vehicle-treated control animals. Single treatments, both
gossypol and TMZ, exerted inhibitory effects on actively
proliferating GBM cells, showing proliferation index of
15.01±2.12 and 14.71±1.66, respectively. Statistical analysis
indicated that the decrease in proliferation in single gossypol and
TMZ-treated animals was significant (Po0.0001 compared with
vehicle-treated tumours). Moreover, combined gossypol/TMZ
treatment revealed a significantly greater decrease in proliferation
compared with single treatments (9.071±0.90, Po0.0001 com-
pared with vehicle-treated tumours, P¼ 0.020 compared with
gossypol-treated tumours, P¼ 0.030 compared with TMZ-treated
tumours) (Figure 5E (Ki67 images) and F). The mean percentage of
TUNEL-positive cells was 3.958±0.6848 in vehicle-treated control
animals. Both single-agent treatments (gossypol and TMZ) exerted
pro-apoptotic effects (16.15±3.278 and 16.83±3.715, respec-
tively). Statistical analysis indicated that the increase in the
percentage of TUNEL-positive cells was significant in single-
agent-treated cohorts of animals (Po0.0001 compared with
vehicle-treated tumours). Moreover, combined gossypol/TMZ
treatment revealed a significantly greater increase in the percentage
of TUNEL-positive cells (29.03±3.233, Po0.0001 compared with
vehicle-treated tumours, P¼ 0.0083 compared with gossypol-
treated tumours, P¼ 0.0149compared with TMZ-treated tumours)
(Figure 5E (TUNEL images) and G). A mean MVD of 49.63±2.39
was observed in vehicle-treated control animals. Single-agent
treatment: gossypol (MVD¼ 41.70±1.31) and TMZ (MVD¼
46.26±2.85) did not show significant inhibitory effects (P¼ 0.119
and P¼ 0.731, respectively, when compared with vehicle cohort).
Nevertheless, when combined gossypol/TMZ treatment was used
MVD was greatly decreased (MVD¼ 32.79±2.66) when com-
pared with vehicle (Po0.0001) and single-agent treatment
protocols (P¼ 0.040—combined treatment vs gossypol and
Po0.0001—combined treatment vs TMZ) (Figure 5E (CD31
images) and H).
Gossypol treatment enhances the efficacy of TMZ treatment
in GBM patient-derived multicellular spheroids and GBM
patient-derived neurosphere cultures. Recent studies have
suggested that the response of GBM patient-derived cultures to
anti-GBM treatment may better reflect potential therapeutic
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efficacy in vitro than adherent GBM cell lines (Singh et al, 2003,
2004; Johannessen et al, 2009). We therefore exposed
GBM patient-derived cultures to treatment for 96 h. Viability
following treatment was assessed using the MTT assay. In contrast
to GBM cell lines (U87MG-luc2, U373, U343 and U251),
GBM patient-derived multicellular spheroids (Figure 6A) and
neurospheres (Figure 6B and C) exhibited greater resistance
to TMZ treatment after 96 h. However, a significant reduction
in cell viability was observed after single-agent gossypol treatment
and combined gossypol/TMZ treatment when compared with
control (Figure 6A–C).
DISCUSSION
We have explored the anti-angiogenic, pro-apoptotic, anti-
proliferative and anti-invasive properties of treatment with the
BH3 mimetic agent gossypol alone and in combination with TMZ,
implementing in vitro and in vivo GBM/endothelial cell models.
In agreement with previous data (Coyle et al, 1994; Voss et al,
2010; Pang et al, 2011), we have shown a dose-dependent cytotoxic
effect of gossypol on human GBM and endothelial cells (Figure 1).
We tested gossypol alone in four GBM cell lines that differ in Mcl-
1 and/or MGMT status (Supplementary Table S1). Our results
revealed that U251 and U373 lines were less responsive to gossypol
following 72 h treatment than other cell lines tested (U87MG-luc2
and U343). We believe that this may be partially due to Mcl-1
protein levels, which have previously been shown to be lower in
U373 and U251 (Day et al, 2011). Inhibition of LDH may further
contribute (Tuszynski and Cossu, 1984; Coyle et al, 1994; Seliger
et al, 2013). Moreover, we have shown that endothelial cells exhibit
greater sensitivity to single-agent gossypol treatment compared
with GBM cells. Greater sensitivity of endothelial cells to gossypol
was also observed previously when compared with sensitivity of
human prostate cancer cells (Pang et al, 2011).
It has previously been reported that gossypol potentiates cell
death induced by TMZ to a greater extend in cell lines with
negative MGMT status (Voss et al, 2010). In order to further test
this finding, we employed isobologram analysis to investigate the
efficacy of combination therapy in four different GBM cell lines of
known MGMT status (Figure 2). Greatest synergism between
gossypol and TMZ was observed in the U343 line (MGMT-
negative) as reported by Voss et al (2010). Some synergism was
observed in the U87MG-luc2 cell line (MGMT-expressing) as also
previously reported (Voss et al, 2010). Nevertheless, U373
(MGMT-low level) and U251 (MGMT-negative) GBM cell lines
(Chahal et al, 2012) demonstrated additive and antagonistic
response to combined drug treatment. Interestingly, it has
previously been reported that U251 and U373 GBM cell line
express low Mcl-1 levels (Day et al, 2011), whereas U87 and U343
cell lines exhibit high Mcl-1 expression levels (Hetschko et al, 2008;
Day et al, 2011; Murphy et al, 2014). We hypothesise that Mcl-1
may impact sensitivity to gossypol regimens. The efficacy of
combined treatment may also be dependent on LDH expression in
a given cell line as in single-agent gossypol treatment (Le et al,
2010; Seliger et al, 2013). Combined gossypol and TMZ treatment
in endothelial cells again exhibited greater sensitivity when
compared with tumour cell lines. This effect was confirmed in
an in vitro endothelial cell–tube-formation assay (Figure 3).
Greater drug synergism in HUVECs was also observed. It has
previously been shown that tumour-associated endothelial cells
express higher levels of the Bcl-2 gene than normal endothelial
cells (Kaneko et al, 2007), resulting in enhanced angiogenesis and
tumour growth (Nor et al, 2001). Moreover, it has further been
shown that gossypol modulates VEGF signalling–mediated angio-
genesis partially contributing to in vivo suppression of prostate
tumour growth. A potent inhibitory effect of gossypol on VEGF-
induced endothelial cell motility was also observed in human
prostate cancer xenografts (Pang et al, 2011).
We also investigated whether gossypol and TMZ combination
could suppress the invasive behaviour of GBM cells. 3-D spheroid
invasion and 3-D matrigel trans-well invasion assays were
employed in order to mimic the complexity and pathophysiology
of in vivo tumour invasion. A significant anti-invasion response to
combined treatment was observed in both assays (Figure 4 and
Supplementary Figure S1). Potent anti-invasive properties of
combined gossypol/TMZ treatment observed in vitro may be due
to perturbation of MMP-2 activity via inhibition of Bcl-2
(gossypol) and TGF-b2 (TMZ). This hypothesis is based on
previously reported data, which indicates that (i) Bcl-2 proteins
may promote tumour cell migration and invasion via induction of
matrix metalloproteinase-2 (MMP-2) and cell surface urokinase-
type plasminogen activator (uPA) (Wick et al, 1998; Choi et al, 2005;
Trisciuoglio et al, 2005), (ii) transforming growth factor-beta 2
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Figure 6. Gossypol in combination with TMZ inhibits human GBM
tumour-derived cell viability. Human GBM tumour-derived
multicellular spheroids were exposed to gossypol (0, 3, 12, 48 mM) with
or without TMZ (0, 100, 200, 400) for 96 h. GBM spheroid viability was
assessed using the MTT assay. Each absorbance value was normalised
to spheroid area at day 0. (A) At least three spheroids were used per
each condition. Human GBM tumour-derived neurosphere cultures
(BT248-luc2 and BT224-luc2) were treated for 96 h with gossypol and/
or TMZ, and cell viability was assessed using the MTT assay. (B and C)
Viability as compared with non-treated controls is shown. Error bars
represent mean±s.e.m., *Po0.05 compared with the control, #Po0.05
compared with TMZ treatment, ##Po0.05 compared with gossypol
treatment, ANOVA and post-hoc Tukey.
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(TGF-b2) enables GBM cell infiltration via regulation of the
expression of MMPs and aVb3 integrin (Wick et al, 2002; Bruna
et al, 2007) and that (iii) TMZ may inhibit (TGF-b2)-induced
invasiveness of GSCs (Zhang et al, 2011). The molecular
mechanism by which Bcl-2 promotes MMP-2 and uPA induction
has not yet been elucidated. However, as Bcl-2 and other anti-
apoptotic Bcl-2 family proteins are increasingly recognised as
physiological regulators of mitochondrial fusion/fission dynamics,
mitochondrial bioenergetics and ER/mitochondrial Ca2þ home-
ostasis (Kilbride and Prehn, 2013), these may be complex. Clearly,
these ‘non-apoptotic’ functions of Bcl-2 and their potential
inhibition by gossypol, which binds to the BH3 binding groove
of Bcl-2 family members, warrant further investigation. Indeed,
BH3 peptides have been shown to induce mitochondrial fission
independent of Bax/Bak-dependent apoptosis signalling (Shroff
et al, 2009).
We also implemented a GBM xenograft model to test the
combination of gossypol and TMZ in vivo. Significantly reduced
tumour burden was observed in animals treated with combination
gossypol/TMZ (after 2 weeks), when compared with single-agent
gossypol therapy. However, no significant reduction in tumour
volume was evident for combination gossypol therapy vs treatment
with TMZ alone. Nevertheless, we observed a reduced number of
animals presenting with visible tumour necrosis in the treatment
groups, particularly in the gossypol/TMZ-combined cohort
(Figure 5D). This observation may indicate that tumour cell
proliferation (as evident via Ki67 staining) is decreased following
combined treatment leading to slower tumour growth and reduced
tumour core necrosis. As previously reported (Soling et al, 2004;
Heikkila et al, 2010; Goldman et al, 2011), we also observed
extensive tumour necrosis in control tumours (Figure 5C) likely
due to the rapid proliferation of U87MG-luc2 GBM cells when
delivered SQ. Histopathological analysis showed that tumours
from gossypol-treated animals have a similar histological archi-
tecture to control tumours. Furthermore, combination therapy
does not manifest as a histologically distinct phenotype when
tumours are compared with those from the single-agent TMZ
treatment group. Moreover, tumours treated with either a single or
combined regimen had decreased numbers of mitotic figures
(Figure 5E). This indicates that tumour cell division is inhibited by
gossypol and/or TMZ and is in line with other reports (Wolter
et al, 2006; Filippi-Chiela et al, 2013; Shen et al, 2014). Examining
more closely viable tumour histology in the non-necrotic regions, a
significant decrease in proliferation was observed following
combined gossypol/TMZ treatment as determined by Ki-67
staining, whereas a significant increase in the percentage of
apoptotic cells was seen in the gossypol/TMZ combination
treatment group as determined by TUNEL staining (Figure 5E, F
and G). This suggests that the activity of gossypol and TMZ
combined elicits cytotoxic and anti-proliferative effects in vivo.
PECAM-1 staining of tumour tissue sections revealed a decrease in
MVD (Figure 5E and H) underscoring the anti-angiogenic
response of combined treatment observed in vitro (Figure 3).
In order to investigate combined gossypol/TMZ therapy in
more clinically relevant patient-derived models and taking into
account GBM heterogeneity, we examined treatment effects in
three primary GBM cultures: patient-derived multicellular spher-
oid cultures (Jarzabek et al, 2013a) and neurospheres derived
from two patients with differencing MGMT clinical status
(BT224-luc2—methylated MGMT and BT248-luc2—unmethylated
MGMT). We observed greater resistance to TMZ treatment in
patient-derived multicellular spheroids and neurosphere cultures
when compared with adherent cell lines. Nevertheless, combined
treatment enhanced primary GBM cell death when compared
with TMZ alone. Extent of response varied for individual patients
tested (Figure 6) likely due to differences in tumour molecular
fingerprints. The genetic profiles of primary GBM biopsy and
in vivo multicellular spheroids showed typical GBM aberrations,
such as: homozyguous deletion of the PIK3R1 gene on
chromosome 5; amplification of chromosome 7 including
EGFR; homozygous deletion of CDKN2A/B and loss of one copy
of chromosome 9; and homozygous deletion of chromosome
10 including the PTEN gene as described previously (Keunen et al,
2011) (Figure 6A, Supplementary Table S1). Among neurosphere
lines (Figure 6B and C), we observed a greater decrease in cell
viability in BT224-luc2 following gossypol alone and gossypol/
TMZ combined treatment. This line, in contrast to BT248-luc2,
showed methylated MGMT clinical status and no homozygous
deletion of CDKN2A/B (Supplementary Table S1).
In summary, data presented herein indicate that implementing
of a gossypol/TMZ combined regimen may be of relevance in the
context of GBM. As presented, gossypol when combined with
TMZ targets multiple ‘hallmarks of cancer’ (tumour proliferation,
cell death and angiogenesis), which may provide benefit in patients
presenting with advanced malignancies. Nevertheless, the extent of
synergy observed is likely to be patient dependent. Mcl-1 and
MGMT status may effect treatment outcome. Our data support
further investigation of gossypol/TMZ combined approach in
clinically relevant orthotopic models and ultimately in human
trials.
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